Andra AP fonden Has $21.93 Million Stake in Insulet Corporation $PODD

Andra AP fonden lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 10.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 77,140 shares of the medical instruments supplier’s stock after selling 9,260 shares during the period. Andra AP fonden’s holdings in Insulet were worth $21,926,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of PODD. Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Insulet in the fourth quarter worth $28,000. Fideuram Asset Management Ireland dac acquired a new position in Insulet in the fourth quarter worth $41,000. Measured Wealth Private Client Group LLC acquired a new position in Insulet in the third quarter worth $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in Insulet in the second quarter worth $51,000.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on PODD shares. UBS Group set a $219.00 price objective on Insulet in a research note on Thursday. Barclays cut their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, JPMorgan Chase & Co. cut their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Trading Down 1.0%

NASDAQ PODD opened at $149.19 on Friday. The stock has a 50-day simple moving average of $171.07 and a 200 day simple moving average of $233.25. The company has a market capitalization of $10.33 billion, a PE ratio of 34.70, a P/E/G ratio of 1.19 and a beta of 1.13. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.